This protocol reports the design of a randomized phase III trial to evaluate the effectiveness of the addition of short-term ADT during 1 month or during 6 months together with an androgen receptor targeted therapy (ARTA) to MDT significantly prolongs PMFS, in patients with hormone sensitive oligorecurrent prostate cancer. Here, AR is linked to Familial prostate cancer.